<DOC>
	<DOC>NCT01443429</DOC>
	<brief_summary>The PK and safety profiles to be examined following a single oral administration of TRK-100STP (120 μg) under fasting conditions to patients with renal impairment and to subjects with normal renal function.</brief_summary>
	<brief_title>A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Beraprost</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<criteria>The eGFR 1 day before study drug administration are stipulated as follows. Subjects with normal renal function : ≥90 Patients with mild renal impairment : ≥60 to &lt;90 Patients with moderate renal impairment : ≥30 to &lt;60 Patients with severe renal impairment : ≥15 to &lt;30 Patients on dialysis Patients who have a history of undergoing renal transplantation Patients with diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>TRK-100STP</keyword>
	<keyword>PK</keyword>
	<keyword>beraprost sodium</keyword>
	<keyword>Japanese males and females</keyword>
	<keyword>Subjects with mild/moderate/severe patients</keyword>
	<keyword>renal impairment</keyword>
</DOC>